Logo h q kinathera 402x 100
Logo h q kinathera 402x 100

KINATHERA

Kinathera is a preclinical biotech developing patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders

  • Stage Product In Development
  • Industry Biotechnology
  • Location Marseille, France
  • Currency EUR
  • Founded November 2015
  • Employees 6
  • Incorporation Type Other
  • Website kinathera.com

Company Summary

Kinathera develops first-in-class oral drugs to treat immuno-inflammatory disorders such as Lupus-like rare or orphan diseases, a billion-euro market with no disease-modifying treatment option.

Our most advanced candidate BT8401, is the most selective inhibitor of an innovative immune target modulating type I interferon production and blocking ICOS signaling. It has solid IP protection and initial in-vivo proof of concept.

Team

  • Pb 20id 202016 20co 20  201mo
    Chief Executive Officer and Founder

    25+ years experience in preclinical, clinical and regulatory development of pharmaceutical products in big pharmas (Parke-Davis, Pfizer, BI,...) and in startup (Trophos, sold to Roche for 420 M€ in 2015).

    Business training @ IFG + Ph.D in Biochemistry.
    10 years of Board experience.

  • 77c17480 0297 45d4 829e 19c310f9ccfc
    Chief Development Officer

    Pharmacy doctor and chemical engineer. 20 years in development planning and execution of pharmaceutical development program in large pharma, Contract research organization and startups (Merck KGaA, Quintiles, Aptuit, Trophos, Coral Biome).
    Previously held preclinical, clinical and CMC roles

Advisors

  • Default avatar
    Dr. John Kellum, MD, Prof in the Dept of Critical Care Medicine and Clinical and Translational Science at University of Pittsburgh. Director of the Center for Critical Care Nephrology and Vice-Chair for Research. He also serves as an Intensivist at UPMC.
    Unconfirmed
    Default avatar
    Damian Marron, experienced life sciences executive with a successful track record of value creation in public and private biotechnology companies through public, VC and IPO, sale to large cap pharma, biotech M&A. Former CEO Trophos, TxCell, ...
    Unconfirmed

Previous Investors

  • Default avatar
    Jacques Meler
    Unconfirmed
    Default avatar
    Ludovic Para
    Unconfirmed